Saleh Lanja, Tang Jonathan, Gawinecka Joanna, Boesch Lukas, Fraser William D, von Eckardstein Arnold, Nowak Albina
.
Clin Chem Lab Med. 2017 Oct 26;55(12):1912-1921. doi: 10.1515/cclm-2016-1129.
We investigate the effect of a high dose of vitamin D3 on circulating concentrations of 25(OH)D3 and its metabolites 24,25(OH)2D3, 3-epi-25(OH)D3, and 1,25(OH)2D3 in healthy individuals with self-perceived fatigue and vitamin D insufficiency [25(OH)D3<50 nmol/L].
One hundred and seven study participants (age 20-50 years) were randomized to receive a single 100,000 IU dose of vitamin D3 (n=52) or placebo (n=55). Vitamin D metabolite concentrations in serum were measured before, and 4 weeks after, supplementation.
Overall, 52% of participants receiving vitamin D3 attained a serum 25(OH)D3 level >75 nmol/L. Among individuals who received vitamin D3, there were significant increases in serum concentrations of 25(OH)D3 and its metabolites 24,25(OH)2D3, 3-epi-25(OH)D3, and 1,25(OH)2D3 at 4 weeks; however, inter-individual variability in these changes was substantial. Positive correlations between serum 25(OH)D3 and 24,25(OH)2D3 and 3-epi-25(OH)D3, and a significant negative correlation between serum 1,25(OH)2D3 and 3-epi-25(OH)D3, were found 4 weeks after supplementation. The 24,25(OH)2D3/25(OH)D3 and 24,25(OH)2D3/1,25(OH)2D3 ratios were significantly increased, compared with baseline, in participants receiving vitamin D3. Baseline 25(OH)D3 concentration was the only factor predictive of the change in 25(OH)D3 after supplementation.
Administration of a single high dose of vitamin D3 leads to a significant increase in concentrations of 25(OH)D3, 24,25(OH)2D3, 3-epi-25(OH)D3 and 1,25(OH)2D3; induction of the catabolic pathway predominates over the production of 1,25(OH)2D3. Due to the high inter-individual variation in the 25(OH)D3 response to supplementation, any given dose of vitamin D is unlikely to achieve optimal vitamin D status in all treated individuals.
我们研究了高剂量维生素D3对自我感觉疲劳且维生素D不足[25(OH)D3<50 nmol/L]的健康个体中25(OH)D3及其代谢产物24,25(OH)2D3、3-表-25(OH)D3和1,25(OH)2D3循环浓度的影响。
107名研究参与者(年龄20 - 50岁)被随机分为接受单次100,000 IU剂量维生素D3组(n = 52)或安慰剂组(n = 55)。在补充前及补充后4周测量血清中维生素D代谢产物浓度。
总体而言,接受维生素D3的参与者中有52%的人血清25(OH)D3水平>75 nmol/L。在接受维生素D3的个体中,4周时血清25(OH)D3及其代谢产物24,25(OH)2D3、3-表-25(OH)D3和1,25(OH)2D3的浓度显著升高;然而,这些变化的个体间差异很大。补充后4周发现血清25(OH)D3与24,25(OH)2D3和3-表-25(OH)D3呈正相关,血清1,25(OH)2D3与3-表-25(OH)D3呈显著负相关。与基线相比,接受维生素D3的参与者中24,25(OH)2D3/25(OH)D3和24,25(OH)2D3/1,25(OH)2D3比值显著升高。基线25(OH)D3浓度是补充后25(OH)D3变化的唯一预测因素。
单次高剂量维生素D3给药导致25(OH)D3、24,25(OH)2D3、3-表-25(OH)D3和1,25(OH)2D3浓度显著升高;分解代谢途径的诱导超过了1,25(OH)2D3的产生。由于个体对补充维生素D3后25(OH)D3反应的个体间差异很大,任何给定剂量的维生素D都不太可能使所有接受治疗的个体达到最佳维生素D状态。